OBJECTIVES: Data of british specialists show, that 5-11 out of 1000 adults have community-acquired pneumonia (CAP) every year, which is 5-12% of all cases of lower respiratory tract infections. The rate of CAP took over 3% in the structure of total respiratory organs disease rate in Ukraine within years 2007-2011.  METHODS: The data of use of antimicrobial preparations (AP): cephalosporins (ceftriaxone), penicillins (amoxicillin and enzyme inhibitor), macrolides (azithromycin) and fluoroquinolones (ciprofloxacin, levofloxacin) for CAP treatment in Kharkiv hospital were used. Analysis of affordability as of index of payment capacity (Ca.s.) of trade names (TNs) provided in pharmaceutical market of Ukraine on indicated INN has been carried out to determine the availability of such preparations for wider population of Ukraine.  RESULTS: Results of the AP affordability analysis made in five groups of INN, showed, that the ratio of therapy of high, middle and low availability for each AP group is different, but in all pharmacological groups except for ceftriaxone group, highly available therapy prevails. Percentage of highly available preparations in the studied groups of INN is: azitromycin (92.2%) > ciprofloxacin (74.3%) > amoxicillin and enzyme inhibitor (67.5%) > ceftriaxone (49.02%) > levofloxacin (46.94 %). As of preparations of middle availability, costing 5% - 15% of average monthly salary, ceftriaxone preparations are most (49.02%), azitromycin preparations are least (6.49%). There are no low availability preparations in ciprofloxacin fluoroquinolone group. Cephalosporins and macrolides group preparations have one AP of low availability. Pharmacotherapy with application of preparations-analogous to levofloxacin, is costly, as 32.7% of preparations of this group are preparations of low availability (16 AP). CONCLUSIONS: Antibacterial preparations needed for treatment of CAP are present in the pharmaceutical market of Ukraine in wide range of preparations and cost. It makes them available to various social groups.